BFI will fund CSIR-CDRI over three years for the research and development of potential healthcare solutions

CSIR-Central Drug Research Institute (CDRI) has announced an alliance with Blockchain For Impact (BFI) to join the BFI-BIOME Virtual Network Program. The collaboration shall nourish biomedical research and innovation to drive interventions in healthcare. The announcement was made at an event in CSIR-CDRI, Lucknow where the Memorandum of Understanding (MoU) was exchanged.

CSIR-CDRI is dedicated to advancing drug discovery and development, aiming to address India’s unmet medical needs and improve public health. This aligns very well with the mission of the BFI-BIOME Virtual Network Program, which aims to foster and support biomedical research and innovation in India to develop healthcare solutions for the Global South. Through this partnership, BFI will fund CSIR-CDRI over three years for the research and development of potential healthcare solutions.

Sandeep Nailwal, the pioneer behind BFI has expressed his excitement, “Partnering with CSIR-CDRI is certainly a step in the right direction for us. It reinforces our commitment to establish a robust healthcare ecosystem in India with home-grown, innovative solutions to the various health afflictions faced by our masses.”

The BFI-BIOME Program is bringing together leading researchers and innovators to create a virtual network that can brainstorm and collaborate to identify and solve pressing healthcare challenges in India.

Dr Gaurav Singh, CEO, BFI, conveyed his thoughts on the newly minted partnership, “With its well-established research facilities and a history of delivering affordable drugs and molecules to the market, partnering with CSIR-CDRI is crucial to advancing our objective of developing sustainable healthcare solutions.”

Reflecting on the new partnership, Dr Radha Rangarajan, Director, CSIR-CDRI, said, “We welcome this partnership with BFI-BIOME to advance our drug discovery portfolio. Our shared commitment to addressing India’s unmet clinical needs make this public-private partnership particularly meaningful. The projects receiving funding will build on novel and pioneering research that has been undertaken by our scientists in the fields of malaria, dengue and metabolic diseases. We look forward to being part of the BFI-BIOME network and jointly creating a new pathway for translational research.”